Ann: First in human trial commences, page-72

Admedus has always been looking at ‘opportunities’, the ‘realization’ of those opportunities have seemingly been squandered up to this date.

Those opportunities with ample funding would have seen this company where?

Though the last deal was a ‘savior’ for the company what if it could could been done earlier?

If this company did not have the MDD to sell off the company would have been where?, it does seem to lurch from one plight to another.

The two new opportunities mentioned; stage of development is?, realization of commercialization is?, funding for will be from?

This company does seemingly have the science ‘but’ not the power to convert that science to dollars at this time, at least for long term RIs.

Why is it that a company could trade at $17 plus, back pre/pre consolidation, with ‘next’ to no science now be trading at less than $5 with its far more valuable IP now seemingly so far advanced?

Problem is where?, ‘problem’ solved will mean how much to long term RIs?

Keeping it real.